Anti-Angiogenesis Treatment with Bevacizumab in Metastatic Breast Cancer

Speaker: Jonas Bergh

J. Bergh comments on 3 studies on the use of bevacizumab in breast cancer: as adjuvant treatment in HER2 negative disease (E5103); as maintenance therapy in the metastatic setting (Arobase); as neoadjuvant treatment (Avataxher) in early HER2 positive breast cancer.

Discussion Points

  • Can you provide a short recap of major results from the use of maintenance treatment in the Arobase (Gineco) study?
  • What results is bevacizumab testing delivering in adjuvant and neoadjuvant trials?
  • How important is the angiogenes pathway in breast cancer?
  • What are the differences in the current bevacizumab licence for metastatic breast cancer between Europe and USA?
  • Can you share your overall conclusion based on the studies with bevacizumab presented at ASCO 2014?